Compared to other currently approved radioligand therapies for prostate cancer, SPLASH is evaluating PNT2002 earlier in the treatment pathway and using fewer and lower doses. The phase 3 SPLASH trial is a multi-center, randomized, open label assessment of PNT2002 in participants with prostate-specific membrane antigen (PSMA)-expressing mCRPC who have progressed on androgen receptor pathway inhibitor (ARPI) therapy. Hansen is Deputy Director for the Division of Cancer Services at Metro South Health, a Medical Oncologist at Princess Alexandra Hospital, and an Associate Professor of Medicine at the University of Toronto and the University of Queensland. Upcoming third-party coverage of the data will include video interviews of Dr. The full poster is available to download at the Company’s investor relations website, located at. “I believe the dosing schedule of four cycles of 177Lu-PNT2002 at 6.8 GBq per cycle every 8 weeks is a unique differentiator offering lower overall whole-body radiation and shorter overall treatment than currently approved PSMA RLT therapies.” Neil Fleshner, Chief Medical Officer of POINT Biopharma. “rPFS is the primary endpoint of the SPLASH trial, making these positive signals from the lead-in cohort extremely promising,” said Dr. Key findings include a median rPFS time of 11.5 months, along with a well-tolerated safety profile with no treatment-related deaths and few treatment-related AEs of grade 3 or higher. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today published a poster at ESMO Congress 2022 containing updated efficacy and safety data from the 27-patient safety and dosimetry lead-in cohort for the Company’s phase 3 SPLASH trial (NCT04647526) evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

10, 2022 (GLOBE NEWSWIRE) - POINT Biopharma Global Inc. PNT2002 was well tolerated with no treatment-related deaths Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including:Ī best radiographic objective response (CR, PR) was achieved in 60% of the 10 participants with evaluable disease at baseline

Phase 10 splash